AI Article Synopsis
- In Japan, the suspension of HPV vaccine recommendations in 2013 led to a significant drop in vaccination rates, prompting researchers to survey obstetricians and gynecologists on their attitudes toward HPV vaccination between 2014 and 2021.
- In 2021, 93.2% of the 340 surveyed doctors supported the government restarting the HPV vaccination recommendation, with 63.2% also believing male teenagers should be vaccinated.
- There was a noticeable increase in the percentage of teenage daughters vaccinated after the suspension, indicating a growing recognition among medical professionals of the importance of HPV vaccination in preventing cervical cancer.
Article Abstract
Background: In Japan, the government suspended HPV vaccine recommendation in 2013, resulting in dropping vaccination uptake to almost zero. We conducted four serial surveys on our colleague' attitude to HPV vaccination between 2014 and 2021. Here, we evaluate the result of the survey in 2021 and compare it to previous surveys.
Methods: The subjects were 567 obstetricians and gynecologists who had been trained in our university hospital or our affiliated hospitals. We used a questionnaire similar in format to those used in 2014, 2017, and 2019.
Results: A total of 340 doctors (60.0%) completed the survey. Among them, 93.2% (317/340) of respondents thought that the government should restart HPV vaccination recommendation, and that 63.2% (215/340) think male teenagers should also vaccinate against HPV. The percentage of teenaged daughters inoculated with HPV vaccination after Japanese government had suspended its recommendation was 43.5% (20/46), an increasing trend from the previous surveys. 39 out of the 46 daughters (84.8%) would be expected to receive full HPV vaccination after they take junior high school entrance examination or after 9-valent HPV vaccination is designated as a national routine-immunization.
Conclusion: This study revealed increasing number of our colleagues think HPV vaccination is necessary for prevention of cervical cancer. The Japanese government's decision to resume its recommendation of the HPV vaccine in November 2021 will lead to a change in the public's thinking and behavior toward the HPV vaccine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10147-022-02173-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and incidence of HPV-related dysplasia of oropharyngeal, cervical, and anal mucosae in Spanish people living with HIV (PLHIV).
AIDS
January 2025
Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada (IBS-Granada), Spain.
Background: Objectives were to determine the prevalence/incidence of HPV-related dysplasia and clearance/acquisition rates of high-risk HPV (HR-HPV) genotypes in genital mucosa of women-LHIV and oropharyngeal and anal mucosa of PLHIV and to evaluate factors related to HR-HPV infection in oropharyngeal mucosa at 12-months.
Material And Methods: Prospective, longitudinal study with 12-month follow-up, enrolled PLHIV between December 2022 and April 2023. At baseline and 12-months, HIV-related clinical and analytical variables were recorded, oropharyngeal mucosa exudates were taken for polymerase chain reaction (PCR) studies for HPV and other sexually transmitted infections, while anal and female genital samples were self-sampled for HPV detection and genotyping by PCR and thin-layer cytology.
Impact of achieving WHO's 90-70-90 targets on cervical cancer elimination and potential benefits in preventing other HPV-related cancers in China: a modelling study.
EClinicalMedicine
November 2024
China-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China.
Background: In the context of the World Health Organization's (WHO) 90-70-90 targets for accelerating cervical cancer elimination, we aimed to assess the impact of achieving these targets and altering intervention factors on cervical cancer elimination in China and their potential benefits from preventing other human papillomavirus (HPV)-related cancers.
Methods: We developed a sexual contact network-Markov model to simulate HPV transmission and the progression of HPV-related cancers (cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers). We projected the population impact of achieving 90-70-90 targets by 2030 on the overall HPV-related cancer burden in China during 2024-2100.
Cross-sectional survey of attitudes towards Human Papilloma Virus (HPV) vaccination amongst surgical dermatologists in the UK.
Br J Dermatol
January 2025
Department of Primary Care & Public Health, School of Public Health, Imperial College London, London, UK.
Immunotherapy in Penile Cancer: A Systematic Review.
Arch Esp Urol
December 2024
Polytechnic University of Coimbra, 3045-093 Coimbra, Portugal.
Penile cancer (PeCa) ranks as the 30th most prevalent cancer globally, predominantly affecting populations in developing countries. Phimosis and Human Papillomavirus (HPV) infection are recognized as the primary risk factors. Early-stage diagnosis typically warrants limited excision or non-invasive therapies.
View Article and Find Full Text PDFCorrection to: Recovery from HPV vaccination deficits caused by the COVID-19 pandemic in Germany: a modeling study of catch-up HPV vaccination among adolescent girls.
Eur J Pediatr
January 2025
Merck & Co., Inc., V&I Outcomes Research, Rahway, NJ, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!